Precision BioSciences announces oral presentation at ASGCT 2026

Precision BioSciences (DTIL) announced that new preclinical data from its PBGENE-DMD program have been accepted for an oral presentation at the American Society of Gene & Cell Therapy, ASGCT, 2026 Annual Meeting, taking place May 11-15, 2026, in Boston, Massachusetts. The accepted abstract highlights new data demonstrating compelling efficacy observed in early-juvenile mice supporting the potential benefit of earlier intervention with PBGENE-DMD in younger patient populations. These data build on previously shared updates showing treatment with PBGENE-DMD leads to durable functional improvement in a humanized Duchenne muscular dystrophy, DMD, mouse model.